Prevention of COVID-19-associated Haemostasis Failure in Patient with Stented Coronary Arteries: a Clinical Case

Introduction. In patients with COVID-19, acute pulmonary lesion grows on inflammation and microvascular thrombosis. Thromboinflammation may develop outside alveolar endothelium and affect endothelium of the heart, kidneys, intestine and other vital organs leading to a multiple-organ insufficiency and possible lethal outcomes. Treatment and prevention of SARS-CoV-2 in the Russian Federation should comply with the Interim Methodological Guidelines of the Russian Ministry of Health that support the global mainstream of COVID-19 containment measures and are updated regularly with new evidence on drug effectiveness, including anticoagulants.

Materials and methods. We review a clinical case of effective treatment of a COVID19 patient with prior coronary surgery from the perspective of the Interim Methodical Guidelines of different editions and international clinical experience in anticoagulant therapy.

Results and discussion. A retrospective analysis of the patient’s treatment demonstrated the efficacy of thromboelastography in rapid assessment of blood hypercoagulation and parnaparin sodium as a drug of choice among low-molecular heparins in a combined setting with dual antiplatelet therapy. Etiotropic therapy rendered to this patient is currently considered less effective.

Conclusion. Combination of anticoagulants with antiaggregants is shown effective under high risks of thrombosis and a background COVID-19 infection, if justified clinically. In cases of complicated diff erential diagnosis, selection of optimal management strategy, anticoagulant and/or antiplatelet therapy monitoring, a good practice is to rely on both the available domestic guidelines and latest meta-analyses combined with international clinical experience.

1. Ciceri F., Beretta L., Scandroglio A.M., Colombo S., Landoni G., Ruggeri A., et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020 Apr 15. Online ahead of print. PMID: 32294809

2. Nardelli P., Landoni G. COVID-19-Related Th romboinflammatory Status: MicroCLOTS and Beyond. General Reanimatology. 2020. Online ahead of print. DOI: 10.15360/1813-9779-2020-3-0-2

3. Th achil J., Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Th rombosis or Pulmonary Embolism? Semin Th romb Hemost. 2020 May 12. Online ahead of print. DOI: 10.1055/s-0040-1712155

4. Bo Diao, Chenhui Wang, Rongshuai Wang, Zeqing Feng, Yingjun Tan, Huiming Wang, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MedRxiv. 2020.03.04.20031120. DOI: 10.1101/2020.03.04.20031120

5. Savioli F. Is there a rationale for heparin use among severe COVID-19 patients? Einstein (Sao Paulo). 2020;18:eED5758. DOI: 10.31744/einstein_journal/2020ed5758

6. Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020 May 21. Online ahead of print. DOI: 10.1056/NEJMoa2015432

7. Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., et al. High risk of thrombosis in patients with severe SARS- CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. DOI: 10.1007/s00134-020-06062-x

8. Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Müller M.C.A., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Th romb Haemost. 2020 May 5. Online ahead of print. DOI: 10.1111/jth.14888

9. Wichmann D., Sperhake J.P., Lütgehetmann M., Steurer S., Edler C., Heinemann A., et al. Autopsy fi ndings and venous thromboembolism in patients with COVID-19. Ann Intern Med. Ann Intern Med. 2020 May 6: M20-2003. DOI: 10.7326/M20-2003

10. Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Bondi- Zoccai G., et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352–71. DOI: 10.1016/j.jacc.2020.03.031

11. Spyropoulos A.C., Raskob G.E. New paradigms in venous thromboprophylaxis of medically ill patients. Th romb Haemost. 2017;117(9):1662–70. DOI: 10.1160/TH17-03-0168

12. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. DOI: 10.1111/jth.14817

13. Iba T., Nisio M.D., Levy J.H., Kitamura N., Th achil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis defi nition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. DOI: 10.1136/bmjopen-2017-017046

14. Young E. The anti‐inflammatory eff ects of heparin and related compounds. Thromb Res. 2008;122(6):743–52. DOI: 10.1016/j.thromres.2006.10.026

15. Li J.P., Vlodavsky I. Heparin, heparan sulfate and heparanase in infl ammatory reactions. Thromb Haemost. 2009;102(5):823–8. DOI: 10.1160/TH09-02-0091

16. Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111(4):625–33. DOI: 10.1160/TH13-09-0730

17. Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti‐infl ammatory eff ects? Th romb Haemost. 2017;117(3):437–44. DOI: 10.1160/TH16-08-0620

18. Morozov K.M., Kolbin A.S., Galankin T.L. Network meta-analysis for Parnaparine eff ectiveness in venous thromboembolic prevention in surgery. Tromboz, gemostaz i Reologia. 2018;(1):31–9 (In Russ.) DOI: 10.25555/THR.2018.1.0821

19. Govil D., Pal D. Point-of-care Testing of Coagulation in Intensive Care Unit: Role of Th romboelastography. Indian J Crit Care Med. 2019;23(Suppl 3):S202–6. DOI: 10.5005/jp-journals-10071-23253